Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Bexarotene. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bexarotene. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Bexarotene. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Bexarotene. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bexarotene. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Bexarotene. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Bexarotene. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bexarotene. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bexarotene. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bexarotene. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bexarotene. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bexarotene. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Bexarotene. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Bexarotene. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Bexarotene. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bexarotene. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Bexarotene. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bexarotene. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Bexarotene. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Bexarotene. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bexarotene. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bexarotene. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Bexarotene. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bexarotene. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Bexarotene. |
| Cladribine | Bexarotene may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Bexarotene. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Bexarotene. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Bexarotene. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Bexarotene. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Bexarotene. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Bexarotene. |
| Floxuridine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Floxuridine. |
| Indomethacin | The risk or severity of adverse effects can be increased when Bexarotene is combined with Indomethacin. |
| Tioguanine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Tioguanine. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Bexarotene is combined with Dexrazoxane. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Bexarotene is combined with Beclomethasone dipropionate. |
| Streptozocin | The risk or severity of adverse effects can be increased when Bexarotene is combined with Streptozocin. |
| Trifluridine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Trifluridine. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Gemcitabine. |
| Betamethasone | The risk or severity of adverse effects can be increased when Bexarotene is combined with Betamethasone. |
| Epirubicin | The risk or severity of adverse effects can be increased when Bexarotene is combined with Epirubicin. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Bexarotene is combined with Chloramphenicol. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Bexarotene is combined with Lenalidomide. |
| Altretamine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Altretamine. |
| Zidovudine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Zidovudine. |
| Cisplatin | The risk or severity of adverse effects can be increased when Bexarotene is combined with Cisplatin. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Bexarotene is combined with Oxaliplatin. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Bexarotene is combined with Propylthiouracil. |
| Pentostatin | The risk or severity of adverse effects can be increased when Bexarotene is combined with Pentostatin. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluticasone propionate. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluocinolone acetonide. |
| Linezolid | The risk or severity of adverse effects can be increased when Bexarotene is combined with Linezolid. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Bexarotene is combined with Triamcinolone. |
| Clofarabine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Clofarabine. |
| Prednisone | The risk or severity of adverse effects can be increased when Bexarotene is combined with Prednisone. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Bexarotene is combined with Pemetrexed. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Bexarotene is combined with Fludrocortisone. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Bexarotene is combined with Mycophenolate mofetil. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Sulfasalazine. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Dacarbazine. |
| Temozolomide | The risk or severity of adverse effects can be increased when Bexarotene is combined with Temozolomide. |
| Penicillamine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Penicillamine. |
| Prednisolone | The risk or severity of adverse effects can be increased when Bexarotene is combined with Prednisolone. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Mechlorethamine. |
| Azacitidine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Azacitidine. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Bexarotene is combined with Methylprednisolone. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Bexarotene is combined with Dactinomycin. |
| Azathioprine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Azathioprine. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Bexarotene is combined with Hydroxyurea. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Bexarotene is combined with Mycophenolic acid. |
| Topotecan | The risk or severity of adverse effects can be increased when Bexarotene is combined with Topotecan. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Mercaptopurine. |
| Thalidomide | The risk or severity of adverse effects can be increased when Bexarotene is combined with Thalidomide. |
| Melphalan | The risk or severity of adverse effects can be increased when Bexarotene is combined with Melphalan. |
| Fludarabine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Fludarabine. |
| Flucytosine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Flucytosine. |
| Procarbazine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Procarbazine. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Bexarotene is combined with Arsenic trioxide. |
| Idarubicin | The risk or severity of adverse effects can be increased when Bexarotene is combined with Idarubicin. |
| Estramustine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Estramustine. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Bexarotene is combined with Mitoxantrone. |
| Lomustine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Lomustine. |
| Dexamethasone | The risk or severity of adverse effects can be increased when Bexarotene is combined with Dexamethasone. |
| Eculizumab | The risk or severity of adverse effects can be increased when Bexarotene is combined with Eculizumab. |
| Decitabine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Decitabine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Nelarabine. |
| Corticotropin | The risk or severity of adverse effects can be increased when Bexarotene is combined with Corticotropin. |
| Cortisone acetate | The risk or severity of adverse effects can be increased when Bexarotene is combined with Cortisone acetate. |
| Paramethasone | The risk or severity of adverse effects can be increased when Bexarotene is combined with Paramethasone. |
| Ciclesonide | The risk or severity of adverse effects can be increased when Bexarotene is combined with Ciclesonide. |
| Stepronin | The risk or severity of adverse effects can be increased when Bexarotene is combined with Stepronin. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Hydroxychloroquine. |
| Castanospermine | The risk or severity of adverse effects can be increased when Bexarotene is combined with Castanospermine. |
| Vorinostat | The risk or severity of adverse effects can be increased when Bexarotene is combined with Vorinostat. |
| 2-Methoxyethanol | The risk or severity of adverse effects can be increased when Bexarotene is combined with 2-Methoxyethanol. |
| Brequinar | The risk or severity of adverse effects can be increased when Bexarotene is combined with Brequinar. |
| Aldosterone | The risk or severity of adverse effects can be increased when Bexarotene is combined with Aldosterone. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Bexarotene is combined with Pirfenidone. |
| Interferon alfa | The risk or severity of adverse effects can be increased when Bexarotene is combined with Interferon alfa. |